Davos-Klosters, Switzerland – AdvaMedDx, the association representing manufacturers of diagnostic tests to promote wellness, improve patient outcomes, and advance public health, today announced a global stakeholder initiative to optimize the use of diagnostic tests in the fight against antimicrobial resistance (AMR). The initiative comes as current trends project antimicrobial resistance could cause up to 10 million deaths annually by 2050.
You are here
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, today issued the following statement regarding FDA’s decision not to release at this time a final guidance on oversight of laboratory developed tests:
WASHINGTON, DC – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement on the Final Report of the Cancer Moonshot Task Force: